YAP1 and non-small cell lung carcinoma: These results were very recently reproduced by other groups in non-small cell lung cancer (NSCLC) and BRAF-inhibitor resistant melanoma cell lines, reinforcing the role of the Hippo effector YAP in the transcriptional regulation of PD-L1 expression [47,48].